Substituted N(-methyl-D3)pyridazine-3-carboxamide or M-(methyl-D3)-nicotinamide compounds as IL-12, IL-23 and/or IFNα modulators

Patent metadata

Field	Value
Publication number	US-12479831-B2
Application number	US-202117997288-A
Country	US
Kind code	B2
Filing date	Apr 27, 2021
Priority date	Apr 28, 2020
Publication date	Nov 25, 2025
Grant date	Nov 25, 2025

Abstract

There are disclosed compounds of the following formula I or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating inflammatory and autoimmune diseases or disorders.

First claim

We claim:

1 . A compound which is

or a pharmaceutically acceptable salt thereof.

2 . A compound which is

or a pharmaceutically acceptable salt thereof.

3 . A pharmaceutical composition comprising one or more compounds according to claim 1 and a pharmaceutically acceptable carrier or diluent.

4 . A method of treating a disease, comprising administering to a patient in need of such treatment a therapeutically-effective amount of a compound according to claim 1 , wherein the disease is an inflammatory or autoimmune disease selected from multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, psoriasis, psoriatic arthritis, Crohn's Disease, Sjögren's syndrome and scleroderma.

5 . A pharmaceutical composition comprising one or more compounds according to claim 2 and a pharmaceutically acceptable carrier or diluent.

6 . A method of treating a disease, comprising administering to a patient in need of such treatment a therapeutically-effective amount of a compound according to claim 2 , wherein the disease is an inflammatory or autoimmune disease selected from multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, psoriasis, psoriatic arthritis, Crohn's Disease, Sjögren's syndrome and scleroderma.

Assignees

• Bristol Myers Squibb Co

Inventors

• Liu Chunjian
• Lin James
• Weinstein David S

Classifications

• C07D487/04 Primary

  Ortho-condensed systems · CPC title

• C07D473/00

  Heterocyclic compounds containing purine ring systems · CPC title

• C07D413/14

  containing three or more hetero rings · CPC title

• C07D405/14

  containing three or more hetero rings · CPC title

• C07D403/14

  containing three or more hetero rings · CPC title